国产大片久久久久久-亚洲国产婷婷久久-久久精品国产不卡-久久不卡精品国产-国产乱码一区二区

產(chǎn)品展示 / products 您的位置:網(wǎng)站首頁 > 產(chǎn)品展示 > 細胞庫 > 細胞系 > 人胰腺癌細胞Capan-2
產(chǎn)品分類

Product category

相關(guān)文章

Related articles

人胰腺癌細胞Capan-2

人胰腺癌細胞Capan-2

簡要描述:青旗(上海)生物技術(shù)發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負責(zé)的態(tài)度,以對科研的高度嚴謹,以嚴格的質(zhì)量控制,為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)!

更新時間:2021-05-27

廠商性質(zhì):生產(chǎn)廠家

瀏覽次數(shù):274

詳情介紹
品牌其他品牌貨號BFN60807521
規(guī)格T25培養(yǎng)瓶x1 1.5ml凍存管x2供貨周期現(xiàn)貨
主要用途僅供科研應(yīng)用領(lǐng)域醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

細胞名稱

人胰腺癌細Capan-2

img1

貨物編碼

BFN60807521

產(chǎn)品規(guī)格

T25培養(yǎng)x1

1.5ml凍存x2

細胞數(shù)量

1x10^6

1x10^6

保存溫度

37

-198

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科        2

 

培養(yǎng)體系

90%DMEM+10%FBS+1% 

培養(yǎng)溫度

37

二氧化碳濃度

5%

簡介

人胰腺癌細Capan-256歲男性供體。該細胞源ATCC

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: NCI RAS program mutant KRAS cell line panel.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2000-049.

Doubling time: 96 hours (PubMed=3019537); 45-60 hours (CLS); ~50-70 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Metabolome analysis.

Omics: Proteome analysis by 2D-DE/MS.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814.

Misspelling: CANPAN-2; In Cosmic 2434087.

基因突變

Heterozygous for KRAS p.Gly12Val (c.35G>T) (PubMed=8026879; PubMed=8426738; PubMed=11169959; PubMed=15367885).

TP53 p.Thr125Thr (c.375G>T); impairs TP53 splicing dramatically (PubMed=8026879; PubMed=24700732).

HLA信息

/

STR信息

Amelogenin        X

CSF1PO        11,12

D3S1358        17,18

D5S818        11,12

D7S820        9,11

D8S1179        12,13

D13S317        11,12 (ATCC; CLS; Cosmic-CLP; KCLB; PubMed=25877200)

11,12,13 (DSMZ)

D16S539        9,13

D18S51        13

D21S11        31

FGA        21,24

Penta D        13,15

Penta E        11

TH01        9.3

TPOX        8

vWA        17 (ATCC; CLS; Cosmic-CLP; PubMed=25877200)

16,17 (DSMZ)

17,19 (KCLB)

參考文獻

PubMed=27259358; DOI=10.1074/mcp.M116.058313

Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J., Daly R.J.

Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.

Mol. Cell. Proteomics 15:2671-2685(2016)

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

 

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=31037374; DOI=10.1007/s00216-019-01814-1

Lagies S., Schlimpert M., Braun L.M., Kather M., Plagge J., Erbes T., Wittel U.A., Kammerer B.

Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry.

Anal. Bioanal. Chem. 411:6319-6328(2019)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

青旗(上海)生物技術(shù)發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負責(zé)的態(tài)度,以對科研的高度嚴謹,以嚴格的質(zhì)量控制,為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)! 



留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

聯(lián)